A Case of Ischemic Colitis Associated with Paclitaxel Loaded Polymeric Micelle (Genexol-PMⓇ) Chemotherapy

다국어 초록 (Multilingual Abstract)

Paclitaxel has been widely used for treating many solid tumors. Although colonic toxicity is an unusual complication of paclitaxel-based chemotherapy, the reported toxicities include pseudomembranous colitis, neutropenic enterocolitis and on rare occasions ischemic colitis. Genexol-PMⓇ, which is a recently developed cremophor-free, polymeric micelle-formulated paclitaxel, has shown a more potent antitumor effect because it can increase the usual dose of paclitaxel due to that Genexol-PMⓇ does not include the toxic cremophor compound. We report here on a case of a 57-year-old man with advanced non-small cell lung cancer and who developed ischemic colitis after chemotherapy with Genexol-PMⓇ and cisplatin. He complained of hematochezia with abdominal pain on the left lower quadrant. Colonoscopy revealed diffuse mucosal hemorrhage and edema from the sigmoid colon to the splenic flexure. After bowel rest, he recovered from his symptoms and the follow-up colonoscopic findings showed that the mucosa was healing. Since then, he was treated with pemetrexed monotherapy instead of a paclitaxel compound and platinum.

참고문헌 (Reference)

1 Sollott SJ, "Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat" 95 : 1869-1876, 1995

2 Kim TY, "Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies" 10 : 3708-3716, 2004

3 Johnson DH, "Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial" 14 : 2054-2060, 1996

4 Kim DW, "Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer" 18 : 2009-2014, 2007

5 Tashiro M, "Ischemic colitis associated with paclitaxel and carboplatin chemotherapy" 98 : 231-232, 2003

6 Klauber N, "Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol" 57 : 81-86, 1997

7 Kim SC, "In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy" 72 : 191-202, 2001

8 Sreenarasimhaiah J, "Diagnosis and management of ischemic colitis" 7 : 421-426, 2005

9 Gelderblom H, "Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation" 37 : 1590-1598, 2001

10 Seewaldt VL, "A retrospective review of paclitaxel-associated gastrointestinal necrosis in patients with epithelial ovarian cancer" 67 : 137-140, 1997